12 Dec 2024

In March 2022, the Competition Commission (Commission) initiated a complaint against Vertex Pharmaceutical Incorporated (“Vertex”), for allegedly engaging in exclusionary practices and excessive pricing in the provision of Kalydeco, Orkambi, Symdeko and Trikafta. These are drugs used to treat cystic fibrosis, a rare genetic disease that primarily affects the lungs and the…